Ensysce Biosciences (ENSC) Stock Price

Ensysce Biosciences Price

NASDAQ·CLOSED
0.56
​
Market closed

Over the last 6 years Ensysce Biosciences grew revenue by 19.2% annually, reaching 5.07 M USD. Earnings per share have declined at 84.1% per year over the last 2 years. For Ensysce Biosciences, the net margin of -200.8% is up versus -825.4% a few years ago.

Ensysce Biosciences stock price

Access this data via the Eulerpool API

Ensysce Biosciences business model & stock analysis

Ensysce Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of solutions for severe pain relief while reducing the fear of and the potential for misuse and overdose. The company is headquartered in La Jolla, California and currently employs 7 full-time employees. The company went IPO on 2017-12-01. The firm is engaged in developing solutions for severe pain relief while reducing the potential for opioid misuse, abuse, and overdose. The firm is using its proprietary technology platforms to develop safer prescription drugs. The firm's development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology - the Trypsin Activated Abuse Protection, (the TAAP platform), and an over-dose protection opioid prodrug technology - the Multi-Pill Abuse Resistant, (MPAR platform). The TAAP platform is designed to improve the care of patients with chronic pain while reducing the human and economic costs associated with prescription opioid drug abuse. The MPAR platform when combined with the Company’s TAAP prodrugs is designed not only to seek to prevent abuse of prescription drugs but also to reduce overdose occurrences.

Frequently asked questions about Ensysce Biosciences

7 analysts currently rate the Ensysce Biosciences stock: 6 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Ensysce Biosciences to generate revenue of 4.60 M USD and earnings per share of -0.15 USD.

Converted at the current exchange rate, the Ensysce Biosciences share trades at 0.50 EUR (0.56 USD).

The Ensysce Biosciences share (ENSC) is listed on 1 stock exchanges, including: NASDAQ (ENSC).

The expected revenue of Ensysce Biosciences is 4.60 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Ensysce Biosciences is -3.86 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Ensysce Biosciences is currently -3.69. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Ensysce Biosciences stock.

The price-to-sales ratio (P/S) of Ensysce Biosciences is currently 3.09. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Ensysce Biosciences stock.

The Eulerpool Quality Score for Ensysce Biosciences is 3/10.

The ISIN of Ensysce Biosciences is US2936025046. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Ensysce Biosciences is ENSC. The ticker symbol is used to trade Ensysce Biosciences shares on the stock exchange.

Fair ValueTerminal
0.47 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue per Employee
723,807.14 USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website ensysce.com
Currency
USD
Initial public offering
Dec 1, 2017
ISIN
US2936025046
Cusip
293602405
Market capitalization
1.97 M USDMicro Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2026
-3.69
P/Ee 2027
-80.33
P/S
P/Se
3.09
EV/EBIT
0.20
P/B Ratio
0.61
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-289.05 %
Last updated Oct 13, 2026, 5:42 AM

Ensysce Biosciences Peer Group

Ensysce Biosciences Ticker

NASDAQ · ENSC